治験一覧
8,963 件中 1661〜1680 件を表示
再発性多発性硬化症（RMS）患者におけるレミブルチニブとテリフルノミドの有効性と安全性の比較
再発性多発性硬化症（RMS）患者におけるレミブルチニブとテリフルノミドの有効性と安全性を比較する
慢性気管支炎の症状を伴う軽度から中等度のCOPD患者における、紙巻きタバコからTHSへの切り替えが疾患進行に及ぼす影響。
The purpose of this study is to demonstrate the slowing of the disease progression including the improvement of Chronic Obstructive Pulmonary Disease (COPD) symptoms in smoking subjects with mild to moderate COPD and a history of chronic bronchitis symptoms (sputum and cough) who switch to the Tobacco Heating System (THS) as compared to those who continue to smoke cigarettes.
癌関連線維芽細胞を標的としたFAPI-PETによる評価
PET / CT examination using \[18F\] FAPI-74 is performed on patients diagnosed with malignant tumor, and the pathological condition is determined by comparing with FDG-PET/CT examination of conventional diagnostic imaging.
慢性腎臓病または心不全患者における高カリウム血症の長期管理に関する観察的前向きコホート研究
This prospective observational research will be conducted to assess the burden of hyperkalemia including treatment and disease burden of patients in a long-term continuous care from various aspects including adherence to the medication for hyperkalemia and HR-QoLs.
再発卵巣がんに対するペムブロリズマブとベバシズマブ併用化学療法、それに続くペムブロリズマブ、ベバシズマブ、オラパリブ併用療法
This trial is a multicenter, single-arm, phase II study evaluating the efficacy of pembrolizumab and bevacizumab in combination with platinum-based chemotherapy (PBC) followed by pembrolizumab, bevacizumab and olaparib as a maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer.This study is planned to enroll eligible 35 patients from multiple study sites in Japan.
同種造血幹細胞移植を受けるAML患者における補助療法および維持療法としてのモクラビモド
This is a multi-center, randomized, double-blinded, placebo controlled trial.
中等度から重度のコントロール不良喘息におけるアツリフラポンの有効性と安全性を評価する研究
This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.
希少がんにおけるマーカー支援選択的治療：知識データベース構築レジストリアジア
This is a registry study that aims to collect patients' data with advanced-stage rare cancer in Asia-Pacific region. Data includes clinical information, details of treatment, prognosis, pathological diagnosis and genetic biomarkers by next-generation sequencing. The relationship between cancer types and prognosis, the effect of treatments, and the cancer type-specific incidence of genomic alterations will be investigated to discover more specific and effective treatment.
卵巣がん患者における完全腫瘍縮小後のニラパリブとベバシズマブの併用療法
Randomized, open label, phase II multicenter study to assess the efficacy niraparib versus niraparib +bevacizumab maintenance in patients with newly diagnosed stage IIIA/B/C high-grade epithelial ovarian cancer with no residual disease after frontline surgery and treatment by adjuvant platinum-basedchemotherapy +/-bevacizumab.
長期腎臓病（慢性腎臓病）および2型糖尿病の成人患者を対象に、フィネレノンとエンパグリフロジンの併用療法がどの程度効果的で、それぞれの単独療法と比較してどの程度安全であるかを検討する研究
Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD. Empagliflozin lowers blood sugar levels by increasing the excretion of glucose from the blood into the urine. In this study, the researchers want to learn how well the combination of finerenone and empagliflozin helps to slow down the worsening of the participants' kidney function compared to either treatment alone. For this, the level of protein in the urine will be measured. The investigators also want to know how safe the combination is compared to either treatment alone. Depending on the treatment group, the participants will either take the combination of finerenone and empagliflozin, or finerenone together with a placebo, or empagliflozin together with a placebo, once a day as tablets by mouth. A placebo looks like a treatment but does not have any medicine in it. Importantly, the participants will also continue to take their other current medicine for CKD and T2D. The participants will be in the study for up to 7.5 months and will take the study treatments for 6 months. During the study, participants will visit the study site 7 times. The study team will: * collect blood and urine samples * check the participants' vital signs * do a physical examination including height and weight * check the participants' heart health by using an electrocardiogram (ECG) * monitor the participants' blood pressure * ask the participants questions about how they are feeling and what adverse events they may be having An adverse event is any problem that happens during the trial. Doctors keep track of all events that happen in trials, even if they do not think the events might be related to the study treatments.
健康な成人男性被験者における[14C]TAS-303の物質収支研究
To evaluate the pharmacokinetics, mass balance recovery, metabolite profile and metabolite identification of \[14C\]TAS-303 following oral single dose
BI 1291583の異なる用量が気管支拡張症の患者に効果があるかどうかを検証する研究
This study is open to adults with bronchiectasis. People can join the study if they produce sputum and have a history of flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 4 groups randomly, which means by chance. Participants in groups 1, 2, and 3 get different doses of BI 1291583. Participants in group 4 get placebo. Placebo tablets look like BI 1291583 tablets, but do not contain any medicine. Participants take the tablets once a day. Participants are in the study for between 6 months and 1 year. During this time, they visit the study site about 10 times and get about 5 phone calls from the site staff. The doctors document when participants experience flare-ups during the study. The time to the first flare-ups is compared between the treatment groups. Doctors also regularly check participants' health and take note of any unwanted effects.
重症フォン・ヴィレブランド病（vWD）の小児におけるボニコグアルファ（rVWF）の研究
The main aim of the study is to evaluate the effectiveness of prophylaxis with vonicog alfa (recombinant von Willebrand factor \[rVWF\]) in children. This study will enroll those participants who have been previously treated with VWF product or with a plasma-derived VWF (pdVWF) product. In this study, participants will be treated with vonicog alfa (rVWF) for 12 months. During the study, participants will visit the study clinic 5 times after treatment initiation.
デュルバルマブを用いた腫瘍学研究を完了した患者を対象としたロールオーバー研究
The rationale of the ROSY-D study is to continue to provide study treatment for patients who have participated in a parent study with Durvalumab and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.
グリコーゲン貯蔵病1a型（GSDIa）患者におけるアデノ随伴ウイルス8型を介したグルコース-6-ホスファターゼ遺伝子導入の研究
The primary objectives of this study are to evaluate the efficacy of DTX401 to reduce or eliminate dependence on exogenous glucose replacement therapy to maintain euglycemia and to maintain or improve the quality of glucose control.
ホルモン受容体陽性／ヒト上皮成長因子受容体2陰性（HR+/HER2-）進行乳がん患者における内分泌療法の実際の治療パターン：日本の医療費請求データ分析
This is a retrospective observational study focusing on patients diagnosed with advanced breast cancer(ABC) in Japan using de-identified claim data from Medical Data Vision (MDV) database. The primary objective of this study is to describe patient demographics, treatment patterns and treatment duration of palbociclib, and subsequent treatment patterns and treatment duration after palbociclib-based therapy among ABC patients in Japan The secondary objective of the study is to describe patient demographics, treatment patterns of ABC patients and treatment duration of endocrine therapy, and subsequent treatment patterns and treatment duration after endocrine therapy among ABC patients in Japan.
優性遺伝性アルツハイマー病ネットワーク試験：認知症予防の機会。遺伝子変異によって引き起こされる早期発症型アルツハイマー病患者における潜在的な疾患修飾治療の研究（DIAN-TU）
To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves disease-related biomarkers and slows the rate of progression of cognitive or clinical impairment.
造血幹細胞移植（HSCT）または固形臓器移植（SOT）を受けた小児および青年におけるサイトメガロウイルス（CMV）感染症の治療におけるマリバビルの安全性、忍容性、薬物動態、および抗ウイルス活性を評価する研究
The main aim of this study is to find out the safety, tolerability and pharmacokinetics (PK) of maribavir for the treatment of CMV infection in children and teenagers after HSCT or SOT and to identify the optimal dose of maribavir using a 200 milligrams (mg) tablet formulation or powder for oral suspension. The participants will be treated with maribavir for 8 weeks. Participants need to visit their doctor during 12-week follow-up period.
薬物治療抵抗性の中等度から重度の運動合併症を伴う進行性特発性パーキンソン病の治療における片側淡蒼球切除術用エクサブレート4000タイプ1.0およびタイプ1.1の承認後レジストリ
このレジストリは、承認後における前向き、多施設、国際、単群、観察レジストリであり、3、6、12ヶ月後、および5年間毎年追跡調査を行います。本レジストリは、60名の被験者を登録し、世界約10施設で実施される予定です。
移植後に新たに診断された多発性骨髄腫患者におけるエルラナタマブとレナリドミドの比較試験
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years